[CAS NO. 57415-44-8] Flecainide hydrochloride

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [57415-44-8]

Catalog

HY-W010950A

Brand

MCE

CAS

57415-44-8

DESCRIPTION [57415-44-8]

Overview

MDL	MFCD19982476
Molecular Weight	450.80
Molecular Formula	C17H21ClF6N2O3
SMILES	O=C(NCC1NCCCC1)C2=CC(OCC(F)(F)F)=CC=C2OCC(F)(F)F.[H]Cl

For research use only. We do not sell to patients.

Summary

Flecainide hydrochloride is a potent and orally active antiarrhythmic agent. Flecainide hydrochloride blocks the cardiac fast inward Na ⁺ current (INa) and the rapid component of the delayed rectifier K ⁺ current. Flecainide hydrochloride prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide hydrochloride has the potential for the research of fetal tachycardias ^[1] ^[2] ^[3] .

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT05213104	Assistance Publique - Hôpitaux de Paris\|Fonds de Dotation ACTION	Patent Foramen Ovale\|Atrial Fibrillation\|Cryptogenic Stroke	March 23, 2022	Phase 3
NCT01833455	University of Wisconsin, Madison	Ventricular Premature Complexes\|Blood Pressure	February 2013	Phase 2
NCT03685149	Wojciech Zareba\|University of Rochester	Arrhythmogenic Right Ventricular Cardiomyopathy	July 31, 2019	Phase 2
NCT02624765	Edgar Jaeggi\|Canadian Institutes of Health Research (CIHR)\|St George´s, University of London\|The Hospital for Sick Children	Fetal Atrial Flutter Without Hydrops\|Fetal Supraventricular Tachycardia Without Hydrops\|Fetal Supraventricular Tachycardia With Hydrops	February 2016	Phase 3
NCT00189319	MEDA Pharma GmbH & Co. KG\|Viatris Inc.	Atrial Fibrillation	September 2003	Phase 4
NCT04837261	Tampere University Hospital\|Helsinki University Central Hospital\|Kuopio University Hospital\|Oulu University Hospital\|Turku University Hospital	Supraventricular Tachycardia	April 15, 2021
NCT00392106	ProRhythm, Inc.	Atrial Fibrillation	April 2006	Phase 3
NCT02110537	Kyunghee University Medical Center\|Ministry of Health & Welfare, Korea	Persistent Atrial Fibrillation	March 2014	Not Applicable
NCT04991896	AHEPA University Hospital\|Skylitseio General Hospital	Atrial Fibrillation\|Arrhythmias, Cardiac	January 1, 2020
NCT00000504	National Heart, Lung, and Blood Institute (NHLBI)	Arrhythmia\|Cardiovascular Diseases\|Heart Diseases\|Ventricular Arrhythmia	September 1982	Phase 2
NCT02248753	Maastricht University Medical Center\|ZonMw: The Netherlands Organisation for Health Research and Development	Atrial Fibrillation	October 2014	Not Applicable
NCT00000526	National Heart, Lung, and Blood Institute (NHLBI)	Cardiovascular Diseases\|Coronary Disease\|Death, Sudden, Cardiac\|Heart Arrest\|Heart Diseases\|Myocardial Infarction\|Myocardial Ischemia\|Ventricular Arrhythmia	August 1986	Phase 3
NCT03539302	InCarda Therapeutics, Inc.	Paroxysmal Atrial Fibrillation (PAF)	May 29, 2018	Phase 2
NCT00002996	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)	Pain	February 1998	Phase 2
NCT02294955	Uppsala University Hospital\|Swedish Heart Lung Foundation	Atrial Fibrillation\|Quality of Life	May 2008	Not Applicable
NCT03587558	Keimyung University Dongsan Medical Center\|Chong Kun Dang Pharmaceutical Corp.	Ventricular Premature Complexes\|Outflow Tract\|Carvedilol	September 5, 2017	Phase 4
NCT01646281	Maastricht University Medical Center	Atrial Fibrillation	August 2012	Phase 4
NCT01117454	Vanderbilt University Medical Center	Catecholaminergic Polymorphic Ventricular Tachycardia	December 2011	Not Applicable
NCT00702117	Hospital Clinic of Barcelona	Atrial Fibrillation\|Tachycardia, Ventricular\|Brugada Syndrome	June 2008	Phase 4
NCT00215774	Atrial Fibrillation Network\|German Federal Ministry of Education and Research\|Meda Pharmaceuticals\|German Research Foundation	Atrial Fibrillation	March 2005	Not Applicable
NCT02302274	NYU Langone Health	Brugada Syndrome\|Arrhythmogenic Right Ventricular Cardiomyopathy	July 1, 2010
NCT03162120	Elpen Pharmaceutical Co. Inc.	Atrial Fibrillation\|Recurrence	September 1, 2018	Phase 2\|Phase 3
NCT00523978	Medtronic Cardiac Rhythm and Heart Failure\|Medtronic	Paroxysmal Atrial Fibrillation	October 2006	Phase 3
NCT05549752	Hippocration General Hospital\|Win Medica\|Pharmassist Ltd	Atrial Fibrillation Paroxysmal\|Coronary Artery Disease Without Residual Ischemia	October 1, 2022	Phase 3
NCT00000556	National Heart, Lung, and Blood Institute (NHLBI)	Arrhythmia\|Atrial Fibrillation\|Cardiovascular Diseases\|Heart Diseases	March 1995	Phase 3
NCT00408473	MEDA Pharma GmbH & Co. KG\|3M\|Viatris Inc.	Atrial Fibrillation		Phase 4
NCT03845010	Maatschap Cardiologie Zwolle	Ventricular Premature Beats	February 12, 2019	Not Applicable
NCT02347111	University of Illinois at Chicago\|Medtronic	Atrial Fibrillation	December 31, 2020	Phase 4
NCT03005366	David Filgueiras-Rama\|Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III\|Hospital San Carlos, Madrid	Paroxysmal Atrial Fibrillation	January 2017	Phase 4

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month